HIV Drug Resistance — A Chink in the Armor

In the resource-rich countries, a remarkable success story has emerged during the past decade in the treatment of human immunodeficiency virus (HIV) infections. There has been strikingly reduced morbidity and mortality among patients treated with potent combination antiretroviral regimens. This success, however, has not been without consequences, the most serious of which are toxic effects associated with current regimens and development of resistance to antiretroviral drugs. In this issue of the Journal, Little et al.1 report that in North America, the proportion of new HIV infections with some degree of drug resistance is increasing. This finding is based on a . . .